During hormone depletion or tamoxifen treatment of breast cancer cells the estrogen receptor apoprotein supports cell cycling through the retinoic acid receptor α1 apoprotein
Open Access
- 7 February 2011
- journal article
- Published by Springer Nature in Breast Cancer Research
- Vol. 13 (1) , R18
Abstract
Current hormonal adjuvant therapies for breast cancer including tamoxifen treatment and estrogen depletion are overall tumoristatic and are severely limited by the frequent recurrence of the tumors. Regardless of the resistance mechanism, development and progression of the resistant tumors requires the persistence of a basal level of cycling cells during the treatment for which the underlying causes are unclear.Keywords
This publication has 54 references indexed in Scilit:
- Biological determinants of endocrine resistance in breast cancerNature Reviews Cancer, 2009
- Antiestrogen-resistant subclones of MCF-7 human breast cancer cells are derived from a common monoclonal drug-resistant progenitorProceedings of the National Academy of Sciences, 2009
- Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast CancerNew England Journal of Medicine, 2009
- Genomic Antagonism between Retinoic Acid and Estrogen Signaling in Breast CancerCell, 2009
- ERα as ligand-independent activator of CDH-1 regulates determination and maintenance of epithelial morphology in breast cancer cellsProceedings of the National Academy of Sciences, 2009
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resourcesNature Protocols, 2008
- Downregulation of erbB3 abrogates erbB2‐mediated tamoxifen resistance in breast cancer cellsInternational Journal of Cancer, 2007
- Synergistic effects of retinoic acid and tamoxifen on human breast cancer cells: Proteomic characterizationExperimental Cell Research, 2007
- Endocrine-responsive breast cancer and strategies for combating resistanceNature Reviews Cancer, 2002
- Inhibition of cyclin D expression in human breast carcinoma cells by retinoids in vitroOncogene, 1997